pCDCAR1 CD19 h(28γ), NK(CAR-NK-2-M328-BG)
The vector of anti-CD19 chimeric antigen receptor(CAR) is constructed for the engineering of NK cells to target Human CD19. The NK cells are genetically modified through transduction with a lentiviral vector expressing scFv of anti-CD19 antibody linked to CD28 transmembrane domain/ endodomain and FcεRIγ signaling domains. And the vector product was designed for the treatment of chronic lymphocytic leukemia (CLL).
Targeting Cell Type
Chronic lymphocytic leukemia (CLL)
Discription of Signaling Cassetes
CD28 (Cluster of Differentiation 28) is one of the proteins expressed on T cells that provide co-stimulatorysignals required for T cell activation and survival. CD28 is the receptor for CD80 (B7.1) and CD86 (B7.2) proteins which are expressed on antigen-presenting cells(APC). CD28 modulates the primary TCR/CD3ζ signal in a different fashion than the late costimulatory elements OX40 and 4-1BB. CD28 enhances the expression of downstream regulators that impact on T-cell proliferation, death, differentiation, and effector functions. CAR+ T cells containing the CD28 endodomain showed strikingly enhanced sustained T cell activation, growth, survival. And CD28 results in a brightly expressed, stable receptor as the transmembrane domain. Including CD28 costimulatory domains in CARs led to enhanced anti-malignancy efficacy.
The high-affinity IgE receptor, also known as FcεRI, or Fc epsilon RI, is the high-affinity receptor for the Fc region of immunoglobulin E (IgE). FcεRI is a key molecule involved in allergic reactions. It is a tetramer composed of 1alpha, 1 beta, and 2 gamma chains. The gamma chains are also subunits of other Fc receptors. The scFv-based CARs engineered to contain a signaling domain from FcεRIγ have been shown to deliver a potent signal for T cell activation and function.
CD19; CD19 molecule; B4; CVID3; B-lymphocyte antigen CD19; differentiation antigen CD19; T cell surface antigen Leu-12; B-lymphocyte surface antigen B4; Chronic Lymphocytic Leukemia; CLL; scFv; CD28; Leukemia; chimeric T cell receptors; chimeric immunoreceptors; chimeric antigen receptors; FMC63
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
||Anti-CD19 (104881) h(41BB-CD3ζ) CAR, pCDCAR1
||Anti-CD19 (FMC63) h(CD28-CD27-FcεRIγ) CAR, pCDCAR1
||Anti-CD19 scFv h(CD3ζ) CARNK, pCDCAR1
||Lenti-CD19 CAR (scFv-CD27-CD3ζ, 47G4) Viral Particle
||Anti-CD19 scFv h(41BB-CD3ζ) CART, pCDCAR1
||Anti-CD19 (104878) h(41BB-CD3ζ) CAR, pCDCAR1
||Lenti-CD19 CAR (scFv-DAP10-CD3ζ, SJ25C1) Viral Particle
||Lenti-CD19 CAR (scFv-41BB-CD3ζ, 105976) Viral Particle
||Anti-CD19 (4G7) h(41BB/CD3ζ) Multi-chain CAR, pCDCAR1
||Anti-CD19 (Denintuzumab) h(CD28-CD3ζ,iCasp-9, IL-15) Self-destruct CAR, pCDCAR1